Stock listing
Hamburg:D8Y Sandoz Group Ltd Aktie
German listing (Hamburg) of Sandoz Group Ltd · home listing SIX Swiss:SDZ
Follow Sandoz Group Ltd into a list and get an email when it puts out news.
Home listing price · SIX:SDZ
80.50 CHF -1.00 (-1.2%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, SIX:SDZ
- Day range
- 80.06 – 81.28 CHFNov 20, 2026
- Volume
- 1.00M sharesNov 20, 2026
- Market cap
- 34.83B CHFAt the close on Nov 20, 2026 · price × 432.7M shares outstanding
- 52-week range
- 52.54 – 86.90 CHFLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- 95.38M CHFMedian day 941,541 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| SIX Swiss:SDZ · Home | 80.50 CHF | -1.00 (-1.2%) | 1,002,530 | 80.80 | 81.28 | 80.06 | 81.50 | Close on Nov 20, 2026 |
| LSE:0SAN | 80.50 CHF | -0.85 (-1.0%) | 29,358 | 81.00 | 81.27 | 80.30 | 81.35 | Close on Nov 20, 2026 |
| OTC:SDZNY | $95.00 USD | -1.15 (-1.2%) | 11,954 | $95.90 | $96.13 | $94.61 | $96.15 | Close on Nov 20, 2026 |
| Frankfurt:D8Y0 | €86.50 EUR | 0.00 (0.0%) | — | €85.50 | €86.50 | €85.50 | €86.50 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · SIX:SDZ · CHF, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 80.50 | -1.00 | -1.2% | 80.80 | 81.28 | 80.06 | 1,002,530 | |
| 81.50 | -1.50 | -1.8% | 83.14 | 83.32 | 81.08 | 1,084,682 | |
| 83.00 | -1.60 | -1.9% | 84.26 | 84.70 | 82.96 | 740,270 | |
| 84.60 | 0.00 | 0.0% | 85.26 | 85.96 | 84.60 | 800,095 | |
| 84.60 | -2.30 | -2.6% | 86.70 | 86.70 | 84.60 | 875,131 | |
| 86.90 | +1.70 | +2.0% | 85.50 | 86.90 | 85.50 | 594,035 | |
| 85.20 | +1.82 | +2.2% | 83.44 | 85.20 | 83.42 | 559,769 | |
| 83.38 | -1.08 | -1.3% | 84.80 | 85.00 | 83.38 | 641,485 | |
| 84.46 | +0.68 | +0.8% | 84.00 | 85.32 | 84.00 | 839,121 | |
| 83.78 | +0.16 | +0.2% | 82.32 | 83.78 | 81.34 | 893,546 | |
| 83.62 | +1.48 | +1.8% | 82.74 | 83.80 | 82.26 | 945,910 | |
| 82.14 | -0.64 | -0.8% | 82.70 | 83.04 | 81.74 | 953,426 | |
| 82.78 | -0.08 | -0.1% | 82.38 | 83.42 | 81.78 | 857,465 | |
| 82.86 | +0.48 | +0.6% | 81.62 | 82.90 | 81.36 | 1,023,340 | |
| 82.38 | -1.00 | -1.2% | 84.00 | 84.24 | 82.30 | 1,958,658 | |
| 83.38 | +3.50 | +4.4% | 81.00 | 85.60 | 80.72 | 2,100,744 | |
| 79.88 | -2.22 | -2.7% | 76.36 | 81.38 | 75.50 | 2,549,769 | |
| 82.10 | -0.26 | -0.3% | 82.30 | 83.38 | 81.50 | 1,712,251 | |
| 82.36 | +1.70 | +2.1% | 80.96 | 83.28 | 80.96 | 1,316,593 | |
| 80.66 | +1.66 | +2.1% | 78.24 | 81.10 | 78.14 | 1,179,816 | |
| 79.00 | +0.52 | +0.7% | 78.78 | 79.40 | 77.94 | 849,811 | |
| 78.48 | +1.36 | +1.8% | 76.86 | 78.48 | 76.52 | 960,347 | |
| 77.12 | +0.54 | +0.7% | 77.00 | 77.88 | 75.80 | 873,851 | |
| 76.58 | -0.60 | -0.8% | 77.00 | 77.46 | 76.36 | 1,228,199 | |
| 77.18 | +1.92 | +2.6% | 75.50 | 77.18 | 74.72 | 1,177,371 | |
| 75.26 | +1.44 | +2.0% | 73.82 | 75.80 | 73.64 | 1,217,432 | |
| 73.82 | +2.18 | +3.0% | 71.46 | 73.82 | 71.18 | 915,336 | |
| 71.64 | +0.62 | +0.9% | 70.96 | 72.60 | 70.80 | 790,576 | |
| 71.02 | +1.30 | +1.9% | 70.24 | 71.02 | 69.72 | 529,303 | |
| 69.72 | +0.40 | +0.6% | 69.48 | 70.50 | 69.20 | 789,191 | |
| 69.32 | -1.42 | -2.0% | 70.50 | 70.50 | 69.20 | 799,264 | |
| 70.74 | +0.98 | +1.4% | 69.22 | 71.14 | 69.22 | 876,464 | |
| 69.76 | -0.24 | -0.3% | 70.72 | 71.70 | 68.24 | 1,270,044 | |
| 70.00 | +1.48 | +2.2% | 69.00 | 70.42 | 68.12 | 1,035,480 | |
| 68.52 | +0.10 | +0.1% | 67.80 | 70.02 | 66.88 | 1,000,473 | |
| 68.42 | -2.44 | -3.4% | 69.82 | 70.34 | 68.42 | 1,125,443 | |
| 70.86 | -1.14 | -1.6% | 72.70 | 73.46 | 70.42 | 972,049 | |
| 72.00 | +0.08 | +0.1% | 71.98 | 73.52 | 71.72 | 1,458,397 | |
| 71.92 | +0.76 | +1.1% | 71.52 | 72.36 | 71.02 | 1,059,012 | |
| 71.16 | +0.38 | +0.5% | 70.48 | 71.26 | 70.14 | 1,057,602 | |
| 70.78 | -0.62 | -0.9% | 71.36 | 72.66 | 70.52 | 1,377,900 | |
| 71.40 | +0.64 | +0.9% | 70.76 | 72.08 | 69.98 | 2,438,997 | |
| 70.76 | +1.04 | +1.5% | 69.90 | 71.34 | 69.90 | 1,180,109 | |
| 69.72 | +1.10 | +1.6% | 69.76 | 70.32 | 68.26 | 1,271,805 | |
| 68.62 | +0.74 | +1.1% | 68.34 | 70.44 | 67.92 | 17,326,209 | |
| 67.88 | +2.16 | +3.3% | 66.32 | 68.04 | 66.14 | 1,518,295 | |
| 65.72 | -0.06 | -0.1% | 65.56 | 67.26 | 65.36 | 1,457,343 | |
| 65.78 | -0.72 | -1.1% | 66.00 | 66.80 | 65.50 | 870,379 | |
| 66.50 | -0.24 | -0.4% | 66.70 | 68.10 | 66.08 | 791,630 | |
| 66.74 | +0.68 | +1.0% | 66.06 | 68.00 | 65.68 | 732,002 | |
| 66.06 | -1.70 | -2.5% | 68.18 | 68.32 | 65.54 | 822,548 | |
| 67.76 | -0.44 | -0.6% | 67.82 | 68.20 | 66.42 | 907,075 | |
| 68.20 | -0.04 | -0.1% | 70.90 | 71.70 | 66.38 | 2,287,917 | |
| 68.24 | -0.12 | -0.2% | 67.94 | 68.50 | 67.44 | 569,824 | |
| 68.36 | -2.00 | -2.8% | 70.24 | 70.44 | 68.34 | 743,041 | |
| 70.36 | +1.50 | +2.2% | 68.76 | 70.72 | 68.76 | 1,077,695 | |
| 68.86 | -0.02 | 0.0% | 68.96 | 69.40 | 68.08 | 926,220 | |
| 68.88 | +0.96 | +1.4% | 68.10 | 69.20 | 67.62 | 788,266 | |
| 67.92 | -0.98 | -1.4% | 68.44 | 68.56 | 67.76 | 995,657 | |
| 68.90 | -1.64 | -2.3% | 71.20 | 71.20 | 68.48 | 901,522 | |
| 70.54 | -0.12 | -0.2% | 70.20 | 71.42 | 69.94 | 691,672 | |
| 70.66 | -2.88 | -3.9% | 73.04 | 73.18 | 70.66 | 714,551 | |
| 73.54 | +0.16 | +0.2% | 73.58 | 73.88 | 72.80 | 624,593 | |
| 73.38 | -0.46 | -0.6% | 73.42 | 74.00 | 72.50 | 486,508 | |
| 73.84 | +0.24 | +0.3% | 73.34 | 74.22 | 73.18 | 660,105 | |
| 73.60 | -0.50 | -0.7% | 74.54 | 75.00 | 73.06 | 937,171 |
- Ticker
- Hamburg:D8Y
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Hamburg
- Currency
- EUR
What changed lately
Latest news release · Nov 16, 2026
Sandoz launches Enzeevu in the US and announces key private label agreement, expanding treatment choice for patients with retinal diseases
Latest earnings call · Aug 5, 2026
Sandoz Group (SIX Swiss: SDZ) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Oct 28, 2026
9M 2026 Earnings Presentation
Earnings · 33 slides
Latest news
Sandoz launches Enzeevu in the US and announces key private label agreement, expanding treatment choice for patients with retinal diseases
Nov 16, 2026
Closed 84.60 (0.0%) on Nov 16, 2026
Sandoz launches Ranluspec® (ranibizumab) in Europe, providing an affordable treatment option for patients with retinal diseases
Nov 12, 2026
Closed 86.90 (+2.0%) on Nov 12, 2026
Sandoz launches new semaglutide treatment option in Brazil, expanding patient access to GLP-1 medicine in key global market
Nov 9, 2026
Closed 84.46 (+0.8%) on Nov 9, 2026
Sandoz reports strong biosimilar-sales momentum; narrowed full-year net-sales range and upgrade to margin guidance
Oct 28, 2026
Closed 79.88 (-2.7%) on Oct 28, 2026
Sandoz opens advanced high-volume drug substance manufacturing centre in Lendava, significantly strengthening in-house capacity and flexibility across leading European biosimilar network
Sep 29, 2026
Closed 72.00 (+0.1%) on Sep 29, 2026
Sandoz announces collaboration with mAbxience to expand patient access to life-enhancing biosimilar medicines
Sep 18, 2026
Closed 68.62 (+1.1%) on Sep 18, 2026
Sandoz issues EUR 500 million bond
Sep 14, 2026
Closed 65.78 (-1.1%) on Sep 15, 2026
Sandoz invests in new drug substance facility in Ljubljana, Slovenia, to expand biosimilar manufacturing capacity
Sep 8, 2026
Closed 68.20 (-0.1%) on Sep 8, 2026
Sandoz announces strategic collaboration with Henlius on up to 10 biosimilars, further expanding industry-leading pipeline
Aug 16, 2026
Closed 74.90 (+2.6%) on Aug 17, 2026
Sandoz delivers strong H1 2026 results, with outstanding biosimilar growth in the second quarter
Aug 5, 2026
Closed 68.14 (+6.0%) on Aug 5, 2026
Sandoz Group Ltd on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 32 in the last 12 months · 50 in all · newest Nov 16, 2026 · oldest 2025
- Calls
- 7 calls with a replay · 7 with a transcript · latest Aug 5, 2026
- Decks
- 25 decks · latest Oct 28, 2026
Where Sandoz Group Ltd is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| SIX Swiss:SDZ · Home listing | SIX Swiss | Switzerland | CHF |
| LSE:0SAN | LSE | United Kingdom | CHF |
| OTC:SDZNY | OTC | United States | USD |
| gettex:D8Y | gettex | Germany | EUR |
| Lang & Schwarz:A3ETYB | Lang & Schwarz | Germany | EUR |
| OTC:SDZXF | OTC | United States | USD |
| Tradegate:D8Y | Tradegate | Germany | EUR |
| Turquoise:SDZZ | Turquoise | United Kingdom | CHF |
| BX Swiss:D8Y | BX Swiss | Switzerland | CHF |
| Aquis:SDZZ | Aquis | United Kingdom | CHF |
| gettex:D8Y0 | gettex | Germany | EUR |
| LS Exchange:A3ETYB | LS Exchange | Germany | EUR |
| VIE:SDZ | Vienna | Austria | EUR |
| BMV:SDZN | BMV | Mexico | MXN |
| Frankfurt:D8Y | Frankfurt | Germany | EUR |
| LS Exchange:A3EVQW | LS Exchange | Germany | EUR |
| BIVA:SDZN | BIVA | Mexico | MXN |
| Frankfurt:D8Y0 | Frankfurt | Germany | EUR |
| Munich:D8Y | Munich | Germany | EUR |
| Stuttgart:D8Y | Stuttgart | Germany | EUR |
| Dusseldorf:D8Y | Dusseldorf | Germany | EUR |
| Dusseldorf:D8Y0 | Dusseldorf | Germany | EUR |
| Hamburg:D8Y · This page | Hamburg | Germany | EUR |
| Hamburg:D8Y0 | Hamburg | Germany | EUR |
| Lang & Schwarz:A3EVQW | Lang & Schwarz | Germany | EUR |
| Munich:D8Y0 | Munich | Germany | EUR |
| Stuttgart:D8Y0 | Stuttgart | Germany | EUR |
| Xetra:D8Y | Xetra | Germany | EUR |
| Hanover:D8Y | Hanover | Germany | EUR |
Valuation
P/E 43.3× against a median of 29.7×: 9th lowest of 11 Pharmaceuticals companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- 39.00B CHF
- P/E
- 43.3×
- EV/sales
- 4.2×
- EV/EBITDA
- 23.6×
- Price/book
- 4.6×
- Gross margin
- 47.4%
- Operating margin
- 12.8%
- Net margin
- 8.6%
- Debt to equity
- 0.7×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Sandoz Group Ltd · SIX:SDZ | US$41.49B | US$46.45B | 43.3× | 4.2× | 23.6× | 4.6× | 8.6% | 0.7× | n/a |
| argenx SE · EURONEXT:ARGX | US$58.86B | US$53.72B | 22.8× | 6.5× | n/a | 7.0× | 31.4% | 0.0× | n/a |
| Roche Holding Ltd · SIX:RO | US$51.16B | US$77.45B | 3.3× | 1.1× | 2.9× | 1.3× | 20.9% | 1.0× | n/a |
| Sun Pharmaceutical Industries Limited · NSE:SUNPHARMA | US$48.80B | US$45.53B | 41.2× | 6.8× | 24.4× | 5.1× | 17.8% | 0.0× | n/a |
| Teva Pharmaceutical Industries Limited · TASE:TEVA | US$46.34B | US$46.29B | 89.8× | 3.3× | 13.5× | 5.8× | 3.7% | 0.5× | n/a |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A · SSE:600276 | US$44.90B | US$38.38B | 33.8× | 7.8× | n/a | 4.5× | 27.0% | 0.0× | n/a |
| Celltrion, Inc. · KRX:068270 | US$36.30B | US$35.65B | 30.8× | 9.7× | 25.9× | 2.7× | 32.2% | 0.0× | n/a |
| Zoetis Inc. · NYSE:ZTS | US$32.69B | US$40.21B | 13.0× | 4.2× | 10.2× | 9.9× | 26.4% | 2.7× | 0.69 |
| Divi's Laboratories Limited · NSE:DIVISLAB | US$32.03B | US$32.03B | 101× | 26.4× | 74.8× | 17.7× | 26.1% | 0.0× | n/a |
| Hansoh Pharmaceutical Group Company Limited · HKEX:3692 | US$23.77B | US$18.81B | 28.6× | 8.4× | 21.6× | 4.2× | 37.0% | 0.1× | n/a |
| United Therapeutics Corporation · NASDAQ:UTHR | US$23.63B | US$21.56B | 19.2× | 6.8× | 15.2× | 3.8× | 38.6% | 0.0× | 0.46 |
| Median of the others | US$40.60B | US$39.29B | 29.7× | 6.8× | 18.4× | 4.8× | 26.7% | 0.0× | 0.57 |
Forecasts
Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 81.63 CHF · Analysts' mean
- EPS, year to Dec 2026
- 4.18 · 16 analysts
- Revenue, year to Dec 2026
- 11.98B · 10 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Pascal Bouye | President, Generics Manufacturing & Supply |
| Leo Bronfman | Senior VP, General Counsel North America |
| Craig Marks | Investor Relations |
| Katie Fischer | IR Coordinator |
| Silvia Siegfried | Senior Director, Investor Relations |
| Tamara Hackl | Senior Director, Investor Relations |
| David Kamenir | Senior VP, Strategy and Growth, North America |
| Elisa Fiorello | Senior VP, People & Organization |
| Jeff Borden | Senior VP, Supply Chain NA |
| Jonathan Kimball | Senior VP, US and Global Public Affairs |
| Len Arsenault | Senior VP, Scientific Affairs |
| Martin Bick | Senior VP, Market Access, Specialty Contracting, & Patient Services |
| Sébastien Ménard | Senior VP, Head of US Generics |
| Shannon Buhl | Senior VP, Commercial Operations |
| Ted Stueck | Senior VP and Chief Ethics, Risk and Compliance Officer |
| Tom Occhipinti | Senior VP, Head of US Biosimilar |
| Keren Haruvi | President North America |
| Kristen Tilak | Senior VP and Chief Financial Officer, North America |
Board
| Director | Role |
|---|---|
| Yannis Skoufalos | Board member |
Events
- Next results
- Feb 17, 2027 (expected)
Calls
| Call | When | Status |
|---|---|---|
| Sandoz Group (SIX Swiss: SDZ) Q2 2026 Earnings Call | Wed, Aug 05, 2026 · 3:30 AM ET | Replay |
| Sandoz Group (SIX Swiss: SDZ) Q1 2026 Earnings Call | Wed, Apr 29, 2026 · 3:30 AM ET | Replay |
| Sandoz Group (SIX Swiss: SDZ) Q4 2025 Earnings Call | Wed, Feb 25, 2026 · 3:30 AM ET | Replay |
| Sandoz Group (SIX Swiss: SDZ) Q3 2025 Earnings Call | Thu, Oct 30, 2025 · 3:00 AM ET | Replay |
| Sandoz Group (SIX Swiss: SDZ) Q2 2025 Earnings Call | Thu, Aug 07, 2025 · 3:00 AM ET | Replay |
| Sandoz Group (SIX Swiss: SDZ) Q1 2025 Earnings Call | Wed, Apr 30, 2025 · 3:00 AM ET | Replay |
| Sandoz Group (SIX Swiss: SDZ) Q2 2024 Earnings Call | Thu, Aug 08, 2024 · 3:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q4 2025 | Dec 31, 2025 | −1.1% |
| Q2 2025 | Aug 7, 2025 · After close | −6.4% |
| Q4 2024 | Mar 4, 2025 | −0.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| 9M 2026 Earnings Presentation | Earnings | 33 slides | Oct 28, 2026 |
| Investor Day (September 2026) | Investor day | 120 slides | Sep 8, 2026 |
| Investor Day (2026) | Investor day | 10 slides | Sep 7, 2026 |
| Investor Day (2026) | Investor day | 10 slides | Sep 7, 2026 |
| Investor Day (2026) | Investor day | 16 slides | Sep 7, 2026 |
| H1 2026 Earnings Presentation | Earnings | 37 slides | Aug 5, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 28 slides | Apr 29, 2026 |
| FY 2025 Earnings Presentation | Earnings | 42 slides | Feb 25, 2026 |
| Investor Presentation (2026) | Investor deck | 36 slides | Feb 24, 2026 |
| J.P. Morgan Healthcare Conference 2026 | Conference | 31 slides | January 2026 |
All 25 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (2026) | Investor deck | 43 slides | 2026 |
| Q3 2025 Earnings Presentation | Earnings | 36 slides | Oct 30, 2025 |
| H1 2025 Earnings Presentation | Earnings | 40 slides | Aug 7, 2025 |
| H1 2025 Earnings Presentation | Earnings | 35 slides | August 2025 |
| Q1 2025 Earnings Presentation | Earnings | 28 slides | Apr 30, 2025 |
| FY2024 Earnings Presentation | Earnings | 41 slides | Mar 5, 2025 |
| Investor Presentation (February 2025) | Investor deck | 32 slides | February 2025 |
| Q3 2024 Earnings Presentation | Earnings | 29 slides | Oct 30, 2024 |
| H1 2024 Earnings Presentation | Earnings | 33 slides | Aug 8, 2024 |
| Q1 2024 Earnings Presentation | Earnings | 25 slides | May 7, 2024 |
| FY2023 Earnings Presentation | Earnings | 37 slides | Mar 13, 2024 |
| J.P. Morgan Healthcare Conference 2024 | Conference | 25 slides | Jan 9, 2024 |
| 9M 2023 Earnings Presentation | Earnings | 23 slides | Oct 24, 2023 |
| Investor Day (June 2023) | Investor day | 142 slides | June 2023 |
| Cowen Healthcare Conference 2015 | Conference | 23 slides | Mar 4, 2015 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| 12-year 4.835% bond Announced: €500M · Bank of America +5 Dealers: Bank of America (co-lead), Mizuho (co-lead), SEB (co-lead), Citi, HSBC, Société Générale Use of proceeds: General corporate purposes including refinancing of existing debt | Sep 14, 2026 | US$577.36M |
| Dual-tranche CHF bonds Closed: CHF 400M raised Use of proceeds: Fully repay USD 750 million equivalent in USD and EUR term loans and extend debt maturities | Mar 31, 2025 | US$452.56M |
| Single-tranche EUR bond Closed: €500M raised Use of proceeds: Fully repay USD 750 million equivalent in USD and EUR term loans and extend debt maturities | Mar 31, 2025 | US$540.48M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 11.2B | 9.12B | 9.98B | 8.86B | 9.68B | 9.56B |
| Cost of revenue | 5.87B | 5.46B | 5.42B | 4.71B | 4.63B | 4.60B |
| Gross profit | 5.28B | 4.93B | 4.56B | 4.15B | 4.20B | 3.95B |
| Research and development | 1.10B | 958.0M | 926.0M | 795.6M | 831.1M | 866.6M |
| Selling, general and administrative | 2.53B | 2.41B | 379.7M | 22.5K | ||
| Operating income | 1.43B | 307.0M | 375.0M | -22.5K | 1.49B | 1.42B |
| Depreciation and amortization | 545.0M | 502.0M | 525.0M | 456.6M | 484.0M | 687.9M |
| EBITDA | 1.97B | 809.0M | 900.0M | 456.6M | 1.98B | 2.11B |
| Interest expense | 220.0M | 235.1M | 202.0M | 84.0M | 64.3M | 73.5M |
| Income before tax | 1.21B | -11.0M | 130.0M | -22.5K | 1.30B | 700.9M |
| Income tax | 293.0M | -12.0M | 50.0M | 361 | 398.9M | 242.0M |
| Net income | 957.5M | 1.00M | 77.0M | -22.9K | 828.4M | 409.0M |
| Earnings per share, basic | 2.19 | 0.00 | 0.18 | -0.00 | 1.92 | 0.95 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 1.74B | 1.19B | 1.11B | 100.0K | 36.4M | 34.5M |
| Short-term investments | -175.6M | |||||
| Receivables | 2.77B | 3.15B | 2.63B | 3.23B | 2.99B | 2.63B |
| Inventory | 2.85B | 2.80B | 2.27B | 2.12B | 1.83B | 2.08B |
| Current assets | 8.16B | 7.80B | 6.37B | 5.98B | 5.07B | 4.99B |
| Property, plant and equipment | 2.78B | 1.99B | 1.85B | 1.90B | 1.93B | 2.08B |
| Goodwill | 8.01B | 7.47B | 6.39B | 7.44B | 7.68B | 7.00B |
| Total assets | 22.0B | 19.9B | 19.4B | 17.6B | 16.0B | 15.9B |
| Accounts payable | 1.85B | 1.52B | 1.59B | 1.10B | 923.9M | 833.6M |
| Current liabilities | 6.89B | 6.31B | 5.70B | 7.91B | 8.37B | 9.15B |
| Long-term debt | 4.70B | 4.39B | 3.98B | 30.0M | ||
| Total debt | 5.68B | 4.85B | 4.55B | 309.0M | 284.3M | 298.8M |
| Total liabilities | 12.6B | 11.7B | 10.8B | 8.80B | 8.55B | 9.04B |
| Shareholders' equity | 9.38B | 8.16B | 7.28B | 77.1K | 7.43B | 6.82B |
| Shares outstanding | 436.8M | 434.0M | 431.2M | 429.9M | 431.0M | 431.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | 1.59B | 656.0M | 362.0M | 1.22B | 1.24B | 1.03B |
| Capital spending | -784.0M | -596.0M | -567.9M | -407.8M | -382.2M | -309.7M |
| Free cash flow | 810.0M | 60.0M | -242.6M | 760.2M | 855.8M | 720.9M |
| Cash from investing | -980.0M | -740.0M | -614.0M | -430.0M | -631.8M | -514.4M |
| Cash from financing | -197.0M | 242.0M | 1.24B | -769.0M | -600.7M | -513.4M |
| Dividends paid | -315.0M | -215.0M | ||||
| Share buybacks | 0 | -12.0M | 0 | |||
| Change in cash | 548.0M | 82.0M | 1.03B | 34.0M | 1.97M | 2.82M |
Cap table
Built by 6ix from Sandoz Group Ltd’s releases · as of Sep 14, 2026
- Common shares
- 432,692,617
- Fully diluted
- 432,692,617
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 432,692,617 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 432,692,617 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Craig Marks | Investor Relations · Since at least Apr 2, 2026 |
| David Kamenir | Senior VP, Strategy and Growth, North America · Since at least Nov 5, 2026 |
| Elisa Fiorello | Senior VP, People & Organization · Since at least Nov 5, 2026 |
| Glenn Gerecke | President, Generics Manufacturing & Supply · Mar 10, 2026 – Nov 5, 2026 · Past |
| Jeff Borden | Senior VP, Supply Chain NA · Since at least Nov 5, 2026 |
| Jonathan Kimball | Senior VP, US and Global Public Affairs · Since at least Nov 5, 2026 |
| Katie Fischer | IR Coordinator · Since at least Apr 2, 2026 |
| Keren Haruvi | President North America · Since at least Aug 5, 2026 |
| Kristen Tilak | Senior VP and Chief Financial Officer, North America · Since at least Nov 5, 2026 |
| Len Arsenault | Senior VP, Scientific Affairs · Since at least Nov 5, 2026 |
All 20 people
| Person | Seat |
|---|---|
| Leo Bronfman | Senior VP, General Counsel North America · Since at least Nov 5, 2026 |
| Martin Bick | Senior VP, Market Access, Specialty Contracting, & Patient Services · Since at least Nov 5, 2026 |
| Pascal Bouye | President, Generics Manufacturing & Supply · Since at least Jul 15, 2026 |
| Sébastien Ménard | Senior VP, Head of US Generics · Since at least Nov 5, 2026 |
| Shannon Buhl | Senior VP, Commercial Operations · Since at least Nov 5, 2026 |
| Silvia Siegfried | Senior Director, Investor Relations · Since at least Apr 2, 2026 |
| Tamara Hackl | Senior Director, Investor Relations · Since at least Apr 2, 2026 |
| Ted Stueck | Senior VP and Chief Ethics, Risk and Compliance Officer · Since at least Nov 5, 2026 |
| Tom Occhipinti | Senior VP, Head of US Biosimilar · Since at least Nov 5, 2026 |
| Yannis Skoufalos | Board member · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Sandoz Group Ltd.